

1/2

RetroGram 1.4

New Patient

Patient Details Laboratory Information HIV Therapy Decision Support Help Exit

Name: Patient ID: abc123 Current Treatment:

Date of Birth: 06/09/1967 1

Tel: 001 2

Sex: M 3

Date of Sample: 02/03/2000

Current Treatment:

amprenavir
amprenavir/r
didanosine
didanosine/r
lopinavir/r
lopinavir/r
nefinavir
nefinavir
ritonavir
saquinavir
saquinavir/r

abacavir
didanosine
lamivudine
stavudine
zalcitabine
zidovudine
zidovudine

delavirdine
efavirenz
nevirapine

Fig. 1

RetroGram 1.4

Patient ID: abc 123

Patient Details Laboratory Information HIV Therapy Decision Support Help Exit

HIV Substitutions Viral Load / CD4 Information

Sample Type: RNA DNA Plasma RNA: 100000 copies/ml

Protease: 10M; 82A CD4: 260 cells/mm3

RT: 215Y; 103N Viral Load: 650 copies/ug DNA

RT66-70 Insertion: Absent Present 4 5

Load file

Fig. 2

2/2

2 RetroGram 1.4

New Patient

Patient ID: abc 123

Print

Save

Help

Patient Details

Laboratory Information

HIV Therapy Decision Support

6

7

8

PIs		NRTIs		NNRTIs	
Current Treatment	New Treatment	Current Treatment	New Treatment	Current Treatment	New Treatment
amprenavir	<input type="radio"/>	abacavir	<input type="radio"/>	delavirdine	<input type="radio"/>
amprenavir/rtv	<input type="radio"/>	didanosine	<input type="radio"/>	efavirenz	<input type="radio"/>
saquinavir	<input type="radio"/>	lamivudine	<input type="radio"/>	nevirapine	<input type="radio"/>
saquinavir/rtv	<input type="radio"/>	zalcitabine	<input type="radio"/>		
indinavir/rtv	<input type="radio"/>	stavudine	<input type="radio"/>		
lopinavir/rtv	<input type="radio"/>	zidovudine	<input type="radio"/>		
nelfinavir	<input type="radio"/>				
indinavir	<input type="radio"/>				
ritonavir	<input type="radio"/>				

Double click a drug name to view the available references supporting its ranking

Interpret Substitutions

Lopinavir is co-formulated with ritonavir.
Nelfinavir: no data on boosting is available.

Fig. 3

Literature references supporting this ranking for zidovudine :

Mayers DL, Japour AJ, Arduino JM, Hammer SM, Reichman R, Wagner KF, Chung R, Lane J, Crumpacker CS, McLeod GX, et al. Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. The RV43 Study Group. *Antimicrob. Agents Chemother.* 1994; 38:307-314.

Hooker DJ, Tachedjian G, Solomon AE, Gursinghe AD, Land S, Birch C, Anderson JL, Roy BM, Arnold E, Deacon NJ. An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3'-azido-2'-deoxythymidine. *J Virol* 1996; 70:8010-8018.

Jellinger, R. M., R. W. Shafer, and T. C. Marigan. 1997. A novel approach to assessing the drug susceptibility and replication of human immunodeficiency virus type 1 isolates. *J. Infect. Dis.* 175:3,561-566.

Kellam P, Boucher CA, Larder BA. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. *Proc Natl Acad Sci U S A* 1992; 89:1934-1938.

OK

Fig. 4